FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like Patient Dies in Cellectis' Groundbreaking CAR-T Trial, Forcing a Halt to Trials September 4, 2017 What You Need to Know About CARMA Therapeutics January 17, 2018 Veloxis Pharma Increases Share Capital In Connection With Exercise Of Warrants September 11, 2017
